Furthermore, Phase II data from the NEOS trial (ChiCTR1800016948), along with smaller studies/real-world datasets, has confirmed that neoadjuvant osimertinib is feasible, effective, and safe in patients with operable EGFR-mutant early-stage (IIA-IIIB) NSCLC[24,25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.